Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Eoganachton Mar 22, 2023 12:18pm
481 Views
Post# 35353877

New Paper by Dr. McFarland's U of Alabama Colleagues

New Paper by Dr. McFarland's U of Alabama ColleaguesDr. McFarland & Dr. Colin Cameron collaborated with the Papish Group at the University of Alabama on this paper.

A degree in chemistry might be helpful if you want to read this one. All I could make out was that out of 8 Ruthenium complexes they checked out, one or two of them might be useful as PSs.

Ruthenium Complexes with Protic Ligands: Influence of the Position of OH Groups and π Expansion on Luminescence and Photocytotoxicity

Olaitan E. Oladipupo, Meredith C. Prescott, Emily R. Blevins, Jessica L. Gray, Colin G. Cameron, Fengrui Qu, Nicholas A. Ward, Abigail L. Pierce, Elizabeth R. Collinson, James Fletcher Hall, Seungjo Park, Yonghyun Kim, Sherri A. McFarland, Igor Fedin and Elizabeth T. Papish

Open Access
 
Received: 23 February 2023 / Revised: 10 March 2023 / Accepted: 14 March 2023 / Published: 22 March 2023
 
(This article belongs to the Special Issue Advances in the Development of Anticancer Drugs)
<< Previous
Bullboard Posts
Next >>